$BHC.TO

Bausch + Lomb Launching Triple Care Preservative Free Lubricant Eye Drops in the United States

Bausch Health, Solta Medical Say Thermage Brand Receives China Trademark Certification

Bausch Health Companies (BHC.TO, BHC) and Solta Medical after the close Thursday said that their Thermage brand received the AAA Well-Known Trademark Certification from the China Trademark Association, a designation awarded to 217 brands across mainland China recognizing brand reputation, consumer confidence and market influence."Joining an elite group of only 217 brands nationwide, this distinction cements Thermage's position as a leader in medical aesthetics and is a powerful validation of the reliability and confidence we have established with consumers and practitioners in China," said chief executive Thomas Appio. "It underscores our commitment to innovation with the highest standards of quality and safety."engineering consulting firm shares closed up $0.03 to $7.48 on Toronto Stock Exchange.

Bausch Health's Aesthetic Business, Solta Medical, Earns "Prestigious Trademark Certification" of Thermage in China

TSX up 455 Points at Midday With Healthcare, Materials, The Best Performers

The Toronto Stock Exchange is up 455 points at midday, partially recouping some of the 630 points lost over five straight days of losses.The best performers are healthcare (+3.6%) and materials (+2.3%). Bausch Health (BHC.TO), which reported an earnings beat after markets closed on Wednesday, is near-10% higher, to $8.41.Real Canadian GDP was up 0.2% in February, Statistics Canada reported today, and the advance reading for March and the first quarter, showed the economy is "far from running on all cylinders".CIBC's Andrew Grantham said: "While growth in Q1 appears close to the Bank of Canada's MPR projection, the apparent stall again in March is a concern regarding momentum heading into the spring. Consumer spending appears to be slowing again, which is understandable given the squeeze from higher gasoline prices as well as a still sluggish labour market. We continue to believe that there's enough slack within the economy to keep core measures of inflation fairly muted, even as the impact of higher energy prices passes through in some areas, which will enable the BoC to leave interest rates on hold through 2026."For its part National Bank said the latest data confirms the Canadian economy has held up in the first quarter despite headwinds. Despite the expected stagnation of the economy in March, GDP by industry shows growth of 1.7% on an annualized basis in the first quarter of the year. Not less than 12 out of 19 sectors posted growth during the quarter, it noted."Under normal circumstances, such growth would be considered decent, but it comes at a time when the population is shrinking, which is holding back the economy's potential GDP. Consequently, GDP per capita is on track to experience its strongest growth in 15 quarters (+2.1% annualized). This is good news for an economy with excess supply and an unemployment rate above its full-employment level," National Bank said."Unfortunately," it added, "past performance is no guarantee of future results regarding this renewed growth. The Canadian economy remains vulnerable due to tariff uncertainty and now, the global geopolitical situation. While higher commodity prices could benefit some industries, the potential upside should be offset by the negative impact on consumers, which are facing a jump in inflation. Weak real estate activity in major urban centers across the country (Toronto, Vancouver, among others) is causing a negative wealth effect, which represents another headwind for consumers."In stocks, Bombardier (BBD-B.TO) shares jumped 17% to $279.86 after it reported an first-quarter earnings beat.

RBC Keeps Sector Perform Rating, US$9.00 Price Target, on Bausch Health After Strong Q1

RBC Capital Markets is maintaining its sector perform rating and US$9.00 price target on the shares of Bausch Health Companies' (BHC.TO) after the company reported upbeat first-quarter results.Analyst David Miehm notes consolidated revenue and adjusted EBITDA beat consensus estimates by ~5%. "Higher-than-planned" residual volumes from several state Medicaid customers also benefited first quarter revenues, he adds, while Solta Medical revenue also rebounded strongly after a depressed fourth quarter.Management reaffirmed 2026 Bausch Health's (RemainCo) guidance, which now includes the anticipated impact of the new tariffs on pharma products, which is expected to be effective late September. The company also reported that all remaining U.S. opt-out litigation payments (~US$158 million across legacy litigation) have been concluded, while RemainCo net debt fell by ~ US$113 million in the quarter.Price: $8.45, Change: $+0.79, Percent Change: +10.31%

Bausch Health Q1 Adjusted Earnings, Revenue, Advance, Beating Estimates

Bausch Health (BHC.TO) up 3.6% in after-hours New York trade, after the company on Wednesday said its first-quarter adjusted earnings and revenue both rose, beating estimates.Adjusted net income, which excludes most one-time items, rose to US$296 million, or US$0.78 per share, from US$220 million, or US$0.59, in the prior-year period. Analysts polled by FactSet had expected US$0.67 per share.Consolidated revenue jumped 12% to US$2.52 billion, beating the US$2.4 billion FactSet forecast.Bausch Health maintained its fiscal 2026 revenue guidance of US$5.25 billion to US$5.4 billion and adjusted EBITDA of US$2.875 billion to US$2.95 billion, both excluding Bausch + Lomb."Our first quarter performance marks twelve consecutive periods of year-over-year growth in revenue, adjusted EBITDA for Bausch Health excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our organization. We continue to invest in our pipeline, including the advancement of larsucosterol to treat alcohol-associated hepatitis, while pursuing business development opportunities aligned with our strategic priorities. With this momentum, we reaffirm our full-year 2026 outlook and remain focused on driving sustainable performance and shareholder value," said chief executive Thomas Appio.Bausch Health shares were last seen up US$0.20, to US$5.79 in after-hours trade. They closed down $0.11 to $7.66 on the Toronto Stock Exchange.

Bausch Health Q1 Consolidated Revenues of US$2.52 Billion

RBC Capital Trims Bausch Health Companies Price Target to US$9.00; Maintains Sector Perform

RBC Capital Market trimmed its price target on the shares of Bausch Health Companies (BHC.TO, BHC) by US$1.00 to US$9.00, with a sector-perform rating ahead of the company's first-quarter earnings.Analyst Douglas Miehm is forecasting revenue of US$2.43 billion, slightly above consensus forecast of US$2.41 billion.The lowered price target of US$9.00 reflects revised estimates and lowered total prescriptions for key drugs, Miehm says, noting that total prescriptions for Xifaxan 550mg formulation declined 6.2% y/y in the first quarter, following a 1.1% y/y decline in the fourth quarter. However, he anticipates volume losses will be partially offset by improved net pricing.Key areas of focus for the earnings include updates on the Xifaxan patent litigation, management's strategic vision for monetizing the Bausch & Lomb (BLCO.TO) asset, and the return to growth at Solta following a depressed fourth quarter, he adds.Bausch Health reports its first-quarter earnings after market close on April 29.Price: $7.81, Change: $+0.12, Percent Change: +1.56%